The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
In this study, we are looking at blood concentrations of Kaletra in HIV positive patients
during pregnancy. The patients will come in for 4 visits lasting ~24hrs. These visits take
place at 20-24 weeks, 30 weeks, 32 weeks and 8 weeks post-partum. At the end of vist 2 (week
30), we will increase your dose to 2 adult Kaletra tablets, and one pediatric Kaletra tablet
(total dose 500/125mg). The dose will remain increased until you are 2 weeks post partum,
then it will return to the standard 2 adult tablets (400/100mg).